CVS Restores Coverage for Eli Lilly's Weight-Loss Drug Zepbound
CVS Restores Coverage for Eli Lilly’s Weight-Loss Drug Zepbound CVS Health, one of America’s largest pharmacy benefit managers, announced it will once again cover Eli Lilly’s weight-loss medication Zepbound (tirzepatide), marking a significant shift in obesity treatment insurance policy in the United States. Zepbound, a GLP-1/GIP dual receptor agonist, has demonstrated remarkable weight-loss results in clinical trials, with patients averaging over 15% body weight reduction within a year. Some participants achieved weight loss exceeding 20%. The drug was initially approved by the FDA for obesity treatment in 2023. ...